Optomed and Thirona Retina establish an AI partnership

Optomed and Thirona Retina, a company specializing in the field of artificial intelligence (AI) assisted retinal image analysis, have entered a partnership for distributing Optomed Aurora® handheld fundus camera together with Thirona Retina’s AI in Europe and selected Middle East and Asian countries.

Thirona Retina is one of the leading companies developing AI for retinal image analysis. Thirona Retina’s flagship AI product RetCADTM analyses images for the presence of age-related macular degeneration and diabetic retinopathy and gives an indication for the presence of glaucoma.

“We are enthusiastic to establish this partnership with Thirona Retina. Optomed and Thirona Retina have a shared and well-aligned vision of providing outstanding quality and usability with our solutions to help detect vision-threatening diseases early. RetCADTM integrated with Optomed Aurora provides a powerful tool with an optimized workflow for eye screening”, commented Laura Piila, Optomed Vice President Devices.

“We are excited to expand our presence to the handheld fundus camera market and make the innovation available to many more patients faster, together with Optomed.  We believe that our shared commitment to quality forms an excellent basis for a successful long-term partnership”, added Mark van Grinsven, Thirona Retina’s Managing Director.

Contact person

Laura Piila,

Vice President Devices, Optomed Plc


Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of eye diseases such as rapidly increasing diabetic retinopathy. In its business, Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

Thirona Retina in Brief

Thirona Retina BV is a Dutch-based company, specializing in the field of AI-assisted retinal image analysis, with RetCAD™ as its flagship product platform.

RetCAD™ is a Class IIa European MDR CE (0344) certified software product using artificial intelligence that analyses color fundus images for the presence of Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma. It assists eye care providers in early diagnosis and grading of vision-threatening diseases. RetCAD™ is available to clinical and optical markets through integration partnerships with all major fundus camera vendors and eye care solutions providers.

Source (text and image): Optomed